AbbVie weekly outlook: consolidates near $220.43 with resistance at $223.50 and $225.27

Traders Union
All News
Financial News
AbbVie rises 0.53% this week

Highlights

ABBV trades below the MA-20 ($221.23) and MA-50 ($225.27), indicating short- and medium-term selling pressure within a strong long-term uptrend above MA-200 ($208.20).
Momentum signals are mixed: daily MACD shows a strong sell, ADX is neutral, RSI tilts slightly bearish, but Stochastic RSI and Bull/Bear Power reflect intraday buyer dominance.
For the next 5 trading days, ABBV is projected to remain between $218 and $225, with 80%+ probability of price increase and resistance at $223.50.

Sentiment boosted as migraine awareness campaign underscores R&D commitment

AbbVie recently launched 'Love in Mind,' an educational initiative focused on raising awareness about the emotional effects of migraines on personal relationships and encouraging open conversations with healthcare providers. This campaign highlights AbbVie's ongoing commitment to support patients across multiple therapeutic areas through research, development, and education.

Neutral momentum persists as mixed indicators stall weekly direction

On the weekly chart, ABBV is trading beneath both the W1 MA-20 ($221.23) and W1 MA-50 ($225.27), while remaining comfortably above the W1 MA-200 ($208.20). The nearest dynamic support is at the MA-200, with resistance marked by the MA-50 and the Ichimoku Kijun line around $223.50. Weekly RSI signals a neutral-to-weak downside bias, while mixed momentum readings from other weekly indicators reflect ongoing indecision, with neither bulls nor bears in full control.

Rangebound outlook as resistance test may trigger breakout or retrace

Across the next 5–7 trading days, ABBV is projected to continue ranging between $218 and $225, with a strong likelihood of sideways price action. Should bullish momentum break through the $223.50 resistance, the asset could target $225 or higher, sustaining the established long-term uptrend. However, a loss of support near $218–$220 could prompt a correction toward the W1 MA-200 at $208.20, although this outcome is less probable given current weekly signals.

Viktoras Karapetjanc, Traders Union expert, sees AbbVie holding firm within a well-established long-term uptrend, even as near-term levels show some pressure. He believes sentiment remains constructive, supported by AbbVie's continued focus on patient-centric innovation, as highlighted by the launch of the 'Love in Mind' initiative this week. Resistance near $223.50 is in focus, but robust support at $218–$220 underpins the bullish structure. The analyst expects the market to offer fresh opportunities as price action consolidates within the $218 to $225 range over the coming week. "With long-term momentum intact and positive developments from management, I expect further growth potential as ABBV attracts quality capital inflows in the near future."

Last time, analysts noted AbbVie was trading below its short- and medium-term moving averages but well above long-term support, with near-term resistance identified at the Ichimoku Kijun. Mixed momentum signals—negative MACD but neutral-to-bullish RSI—combined with elevated intraday volatility, indicate short-term consolidation is likely within a defined range, while a sustained break above resistance could revive upside momentum.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.